Literature DB >> 11127393

High-dose methotrexate in childhood all.

P J Moe1, A Holen.   

Abstract

An event-free survival is currently achieved in 70-80% of children diagnosed with acute lymphocytic leukemia (ALL). A decline in the long-term sequalae from therapy is a challenge at present. Due to the high incidence of central nervous system (CNS) relapse in ALL patients, cranial irradiation was introduced as a prophylactic measure in the beginning of the 1970s. Cranial irradiation, however, may cause secondary malignancies in the CNS. In recent years neurotoxicities have been demonstrated to follow cranial irradiation in a large proportion of ALL patients. Because of these deleterious effects, most ALL protocols are limited to the combination intrathecal and intravenous methotrexate as the standard for CNS prophylaxis. In the 1970s, an intermediate dose was administered, while from the 1980s a high dose of methotrexate was combined with intrathecal methotrexate. The regular methotrexate dose of later years has been in the range of 5-8 g/m2. The intravenous methotrexate dose has actually varied from 2 to 33.6 g/m2. The highest dose, 33.6 g/m2, has been without intrathecal instillation. In a study from Norway, high-dose methotrexate (6-8 g/m2) was used, and only two (2.2%) of 89 ALL cases showed CNS relapse, both of reversible kind. In the United Kingdom, a randomized controlled study was started in 1990. Results published so far are based on a segment of cases characterized by standard risk and white blood cell count below 50 x 10(9); a 4% reduction in CNS relapse was found for high-dose methotrexate in comparison to those treated only with long-term intrathecal methotrexate. The use of methotrexate unalterably warrants some precautions. Rescue therapy with folinic acid is usually started 36 h after initiating the methotrexate infusion. Steps are also taken to secure adequate intake of fluids and alkalinization of the urine. Provided irradiation is avoided, neurotoxicities rarely occur. For regular high-dose methotrexate adverse effects mostly involve mucositis and myelosuppresion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127393     DOI: 10.1080/08880010050211321

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  7 in total

1.  High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Authors:  T Sakura; F Hayakawa; I Sugiura; T Murayama; K Imai; N Usui; S Fujisawa; T Yamauchi; T Yujiri; K Kakihana; Y Ito; H Kanamori; Y Ueda; Y Miyata; M Kurokawa; N Asou; K Ohnishi; S Ohtake; Y Kobayashi; K Matsuo; H Kiyoi; Y Miyazaki; T Naoe
Journal:  Leukemia       Date:  2017-09-15       Impact factor: 11.528

2.  Cryptosporidium gastroenteritis in Egyptian children with acute lymphoblastic leukemia: magnitude of the problem.

Authors:  S M A Hassanein; M M S Abd-El-Latif; O M Hassanin; L M S Abd-El-Latif; N I Ramadan
Journal:  Infection       Date:  2011-12-22       Impact factor: 3.553

3.  F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia.

Authors:  Marilyn J Hockenberry; Olga A Taylor; Patricia M Gundy; Adam K Ross; Alice Pasvogel; David Montgomery; Phillip Ribbeck; Kathy McCarthy; Ida Moore
Journal:  Biol Res Nurs       Date:  2013-08-15       Impact factor: 2.522

4.  Continuous enteral administration can overcome the limited capacity to absorb glucose in rats with methotrexate-induced gastrointestinal mucositis.

Authors:  Margot Fijlstra; Edmond H H M Rings; Theo H van Dijk; Torsten Plösch; Henkjan J Verkade; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2012-09-26       Impact factor: 3.603

5.  Methotrexate Neurotoxicity Is Related to Epigenetic Modification of the Myelination Process.

Authors:  Yu-Chieh Chen; Jiunn-Ming Sheen; Su-Chen Wang; Mei-Hsin Hsu; Chih-Cheng Hsiao; Kow-Aung Chang; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

6.  The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients.

Authors:  Chanchai Traivaree; Napakjira Likasitthananon; Chalinee Monsereenusorn; Piya Rujkijyanont
Journal:  Cancer Manag Res       Date:  2018-10-10       Impact factor: 3.989

7.  Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.

Authors:  Nur Melani Sari; Lulu E Rakhmilla; Muhammad Hasan Bashari; Zulfan Zazuli; Nur Suryawan; Susi Susanah; Lelani Reniarti; Harry Raspati; Eddy Supriyadi; Gertjan J L Kaspers; Ponpon Idjradinata
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.